TNXP stock forecast
Our latest prediction for Tonix Pharmaceuticals Holding Corp.'s stock price was made on the March 29, 2019 when the stock price was at 2.41$.
In the short term (2weeks), TNXP's stock price should outperform the market by 7.68%. During that period the price should oscillate between -10.92% and +26.69%.
In the medium term (3months), TNXP's stock price should outperform the market by 8.18%. During that period the price should oscillate between -24.14% and +69.66%.Get email alerts
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -26.81$ per share.
The book value per share is 1.67$
Three months stock forecastMarch 29, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|